Demyelinating disease

Good News--MS Drugs Taken While Breastfeeding May Not Affect Child Development

Retrieved on: 
Tuesday, March 5, 2024
NMOSD, Social media, Hellwig, Nervous system, Alzheimer's disease, MD, Ofatumumab, Stroke, German, Pregnancy, Life, Risk, Annual general meeting, Multiple sclerosis, DSM-IV codes, AAN, Health, Migraine, Parkinson's disease, Hypoesthesia, Fatigue, Ruhr University Bochum, Mother, Paresthesia, Infant, Concussion, Spinal cord, Breast milk, Epilepsy, Sclerosis, Disease, Child, Rituximab, Natalizumab, Optic nerve, Brain, Demyelinating disease, Research, Immune system, American Academy, Birth control

MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.

Key Points: 
  • MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.
  • For the study, researchers used the German MS and Pregnancy Registry to identify 183 infants born to mothers taking monoclonal antibodies while breastfeeding.
  • The first exposures to the medications through breastfeeding ranged from the day a child was born to the ninth month of life.
  • After comparing infants exposed to the medications to infants not exposed, researchers found no differences in their health or development.

Anokion Announces Clinical Progress with KAN-101 and ANK-700

Retrieved on: 
Tuesday, September 12, 2023
Health, Neurology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Demyelinating disease, Myelin, Safety, Spinal cord, Clinical trial, SAD, Brain, Multiple sclerosis, CNS, MS, Incidence, RRMS, Patient, Autoimmune disease, Immune tolerance, Immune system, Assessment, MAD, Liver, Coeliac disease, Neuroinflammation, Vaccine, Pharmaceutical industry

Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today reported progress for its clinical-stage programs, KAN-101 and ANK-700.

Key Points: 
  • Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today reported progress for its clinical-stage programs, KAN-101 and ANK-700.
  • Anokion has designed ANK-700 to re-educate the immune system by inducing antigen-specific tolerance to myelin-based autoantigens to reduce neuroinflammation in the brain and spinal cord.
  • The study will continue with a 12-month safety follow-up expected to complete in the first half of 2024.
  • Anokion anticipates reporting full results from its MoveS-it clinical trial in the second half of 2024.

Globally Recognized Expert in Rare Neurologic Diseases, Dr. Michael Levy, Joins Trethera Scientific Advisory Board

Retrieved on: 
Tuesday, September 5, 2023
Demyelinating disease, DSM-IV codes, Optic neuritis, Central nervous system, University, Johns Hopkins Hospital, Myelin, Spinal cord, Cancer, Coronavirus Scientific Advisory Board, American Academy, Brain, Inflammation, Multiple sclerosis, Doctor of Philosophy, Associate, MS, Harvard Medical School, Nerve, CNS demyelinating autoimmune diseases, Patient, Division, Optic nerve, ADEM, Baylor College of Medicine, Hospital, Massachusetts General Hospital, American Academy of Neurology, Acute disseminated encephalomyelitis, Peripheral nervous system, Pharmaceutical industry, Philosophy, MD, Neurology

Dr. Levy will have a particular focus on evaluating the clinical development of Trethera’s lead asset, TRE-515, in demyelinating autoimmune diseases.

Key Points: 
  • Dr. Levy will have a particular focus on evaluating the clinical development of Trethera’s lead asset, TRE-515, in demyelinating autoimmune diseases.
  • When the myelin sheath is damaged, nerve impulses slow or even stop, causing neurological problems.
  • “We are honored to have Dr. Levy join our advisory board,” said Dr. Ken Schultz, Chairman and CEO of Trethera.
  • “He is a leading authority on rare neurologic autoimmune diseases and has expertise in both early and late-stage clinical trials.

Patient CSF Cell Counts: How to Improve Accuracy and Save Time, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, May 30, 2023
Demyelinating disease, MLS, US Foods, Malignancy, Food and Drug Administration, MBA, Cerebrospinal fluid, ASCP, Hospital, Bleeding, MercyOne, Physician, American Women's Hospitals Service, CSF, Diagnosis, MercyOne Des Moines Medical Center, FDA, Meningitis, Food, Medical device, Medical imaging

TORONTO, May 30, 2023 /PRNewswire-PRWeb/ -- Accurate and timely cerebrospinal fluid (CSF) cell counts are critical in the diagnosis of meningitis, malignancy, demyelinating disease and hemorrhage. Due to historical limitations with the linearity of automated analyzers, CSF cell counts have traditionally been performed manually with a hemocytometer and the aid of a brightfield optical microscope. Manual cell counting is time-consuming, subjective due to reliance on human interpretation and requires a high degree of skill. This poses significant challenges for clinical laboratories of all sizes facing unprecedented staffing shortages. It also poses challenges for physicians who rely on timely results to provide appropriate patient management.

Key Points: 
  • In this free webinar, learn about the importance of accurate and timely cerebrospinal fluid (CSF) cell counts for appropriate patient management.
  • Attendees will gain insight into a US Food and Drug Administration (FDA)-cleared advancement in CSF cell counting technology with linearity down to 0 cells/µL.
  • The featured speakers will discuss the positive impact of automating patient CSF cell counts through case studies.
  • TORONTO, May 30, 2023 /PRNewswire-PRWeb/ -- Accurate and timely cerebrospinal fluid (CSF) cell counts are critical in the diagnosis of meningitis, malignancy, demyelinating disease and hemorrhage.

Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor

Retrieved on: 
Wednesday, January 25, 2023
Rewind, Remyelination, Neurodegeneration, CNS, General partnership, Neuron, Demyelinating disease, Multiple sclerosis, Therapy, Degenerative disease, Total survey error, Central nervous system, Depression, Patient, Anxiety, Irritability, Death, PMV, Doctor of Philosophy, Pharmaceutical industry

Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that it has raised additional funding, with Sunstone Life Science Ventures A/S joining as a new investor and with participation of existing investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.

Key Points: 
  • Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics , a company developing first-in-class treatments for demyelination-associated diseases, today announced that it has raised additional funding, with Sunstone Life Science Ventures A/S joining as a new investor and with participation of existing investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.
  • Claus Andersson, PhD, General Partner at Sunstone Life Science Ventures A/S, will join Rewind Therapeutics´ Board of Directors.
  • "We are delighted to welcome Sunstone Life Science Ventures as a new investor alongside the continued support by our existing investor syndicate," said Anja Harmeier, Chief Executive Officer at Rewind Therapeutics.
  • "Moreover, Rewind has a strong patent estate and a team with long research and development expertise in the field of remyelination therapeutics.

Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team

Retrieved on: 
Tuesday, November 29, 2022
GlaxoSmithKline, Doctor of Philosophy, Rewind, GSK, Remyelination, Head, Demyelinating disease, University, Therapy, Bachelor of Science, Patient, Neuroscience, Molecular genetics, Discovery, Optic neuritis, Consultant, PMV, Nerve injury, Biology, Multiple sclerosis, University of Warwick, Roche, Ludwig Cancer Research, Total survey error, Drug discovery, HIV disease progression rates, Medical device, Pharmaceutical industry, Research

Leuven, Belgium, November 29, 2022 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that Dr. Stephen Burbidge has been appointed to the Company´s management team as Head of Research and Discovery.

Key Points: 
  • Leuven, Belgium, November 29, 2022 --- Rewind Therapeutics , a company developing first-in-class treatments for demyelination-associated diseases, today announced that Dr. Stephen Burbidge has been appointed to the Companys management team as Head of Research and Discovery.
  • "We are delighted to welcome Stephen Burbidge at Rewind Therapeutics," said Anja Harmeier, Chief Executive Officer at Rewind Therapeutics.
  • "Rewind Therapeutics is focusing on remyelination therapies, an area of increasing importance in treating neurological and nerve-related diseases," said Dr. Stephen Burbidge.
  • Rewinds team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics.

Cellevolve Bio Receives FDA Clearance of IND Application and Orphan Drug Designation for CE-VST01-JC for the Treatment of Progressive Multifocal Leukoencephalopathy (PML)

Retrieved on: 
Tuesday, October 25, 2022
SAN, Human polyomavirus 2, Therapy, IND, Science, EMA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, JC, Patient, Degenerative disease, Progressive multifocal leukoencephalopathy, Food, Company, Immunodeficiency, CEO, NORD, Tropical disease, Social media, Safety, CNS, PML, Demyelinating disease, JCV, FDA, Central nervous system, MRS, Vaccine, Pharmaceutical industry, EU

CE-VST01-JC also received FDA orphan drug designation.

Key Points: 
  • CE-VST01-JC also received FDA orphan drug designation.
  • "We are thrilled to have received IND clearance to begin our Phase 2 clinical study," said Derrell Porter, M.D., Founder and CEO, Cellevolve.
  • PML is a demyelinating disease of the central nervous system (CNS) caused by JCV and occurs in immunocompromised patients.
  • There are no FDA or EMA approved treatments for this condition, which affects ~ 4,000 individuals in the US and Europe annually.

Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer

Retrieved on: 
Wednesday, October 19, 2022
Rewind, Nerve injury, Disease, Therapy, CSO, PD, Swiss Federal Institute of Aquatic Science and Technology, Science, Multiple sclerosis, Optic neuritis, Patient, Total survey error, Research, HIV disease progression rates, University, Company, Drug discovery, Doctor of Philosophy, Industry, Remyelination, CNS, Demyelinating disease, Head, University of Zurich, California Institute for Quantitative Biosciences, Swiss Federal Institute of Technology, Molecular neuroscience, Neurodegeneration, PMV, Pharmaceutical industry

Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that Irene Knuesel, PhD, PD, has been appointed as the Company´s Chief Scientific Officer.

Key Points: 
  • Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics , a company developing first-in-class treatments for demyelination-associated diseases, today announced that Irene Knuesel, PhD, PD, has been appointed as the Companys Chief Scientific Officer.
  • "We warmly welcome Irene as our new CSO and are excited that she joins Rewind," said Anja Harmeier, Chief Executive Officer at Rewind Therapeutics.
  • Our goal is to progress to a clinical-stage portfolio company and we know Irene will play a significant role in advancing Rewind."
  • "Rewind Therapeutics has built a great team and comprehensive expertise in remyelination," said Irene Knuesel, Chief Scientific Officer at Rewind Therapeutics.

Rune Labs Partners with Coastal Research Institute to Identify Biomarkers of Multiple Sclerosis Lesions using AI Platform to Analyze Patient Neurophysiological Data

Retrieved on: 
Thursday, July 14, 2022
Eclipse, Technology, Disease, EDSS, Nerve, José Benito Vives de Andréis Marine and Coastal Research Institute, Leadership, Neuropathic pain, Multiple sclerosis, Patient, CRI, Spine, SAN, Demyelinating disease, MD, Brain, Physician, Runes, Parkinson's disease, Pathology, Spinal cord, Machine learning, Trial of the century, Therapy, Remyelination, Standard electrode potential, Data analysis, MS, Research, Immune system, Degenerative disease, Physiology, Doctor of Philosophy, Software, Institute, Biomarker, Pharmaceutical industry, Medical imaging

SAN FRANCISCO, July 14, 2022 /PRNewswire/ -- Rune Labs, a precision neurology software and data platform company, today announced it is enrolling patients with multiple sclerosis (MS) in a study to identify neurophysiological biomarkers of the disease. The company has partnered with Coastal Research Institute (CRI) to measure demyelination in patients with spinal cord stimulators using closed loop technology. Demyelination is a hallmark symptom of MS that occurs when the immune system attacks nerve fibers, causing lesions in the brain and spine. 

Key Points: 
  • The company has partnered with Coastal Research Institute (CRI) to measure demyelination in patients with spinal cord stimulators using closed loop technology.
  • Clinical scores currently used as endpoints and screeners in trials are imprecise and do not always correlate with lesion activity.
  • "Rune's AI platform enables us to take raw brain data and convert it into actionable biomarkers of myelination."
  • Rune Labs' first-in-class precision neurology software platform uses machine learning to capture and analyze electrophysiological brain data to uncover previously overlooked markers of disease.

INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray Matter at 3rd European Conference on Neuroinflammation

Retrieved on: 
Tuesday, May 10, 2022
Neurodegeneration, RDT, TNF, U.S. Securities and Exchange Commission, AD, Private Securities Litigation Reform Act, Inflammation, Brain, Immunology, MRI, Neuroinflammation, Myelin, NASDAQ, Time, GLOBE, Company, Demyelinating disease, Remyelination, MS, Food, Patient, Security (finance), White matter, Degenerative disease, European Conference of Postal and Telecommunications Administrations, FDA, Natural killer cell, Cancer, Grey, US Foods, Marketing, Disease, Conference, Adi, VP, Research, Cell, Vaccine, Pharmaceutical industry, Medical imaging

Boca Raton, Florida, May 10, 2022 (GLOBE NEWSWIRE) --  Inmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease is pleased to announce that Professor Lesley Probert Ph.D., head of the department of Immunology at the Hellenic Pasteur Institute in Athens, Greece will be presenting data on the effects of tumor necrosis factor (TNF) in MS at the 3rd European Conference on Neuroinflammation concluding in London today. 

Key Points: 
  • Professor Probert has been researching the role of TNF in promoting demyelination (destruction of myelin) for more than a decade.
  • When the myelin sheath is damaged, nerve cells cannot transmit signals efficiently and, if the damage persists, the cells undergo neurodegeneration and die.
  • The data presented today show that XProTM also promotes remyelination within the gray matter of the brain by inducing the brains natural repair mechanisms.
  • Neutralization of soluble TNF with XProTM activates pro-microglial and pro-astroglial responses to clear (phagocytize) degenerated myelin and promote remyelination in cortical areas.